Ximelagatran prevented secondary venous thromboembolism


Clinical impact ratings GP/FP/Primary care ★★★★★★★ IM/Ambulatory care ★★★★★★★★ Haematology ★★★★★★★★★

What is the long term efficacy and safety of ximelagatran after 6 months of standard anticoagulant therapy for secondary prevention of venous thromboembolism (VTE)?

METHODS

- Design: randomised placebo controlled trial (Thrombin Inhibitor in Venous Thromboembolism [THRIVE III]).
- Allocation: concealed.
- Blinding: blinded (clinicians, patients, data collectors, outcome assessors, and data analysts).*
- Follow up period: 18 months.
- Setting: 142 centres in 18 countries.
- Patients: 1233 patients who were >18 years of age with symptomatic, objectively confirmed deep venous thrombosis (DVT) or pulmonary embolism (PE) and had received anticoagulant therapy for 6 months with no recurrent VTE event. Exclusion criteria: indication for continuous anticoagulant therapy, haemoglobin level <9.0 g/dl, platelet count <90 000/mm³, pregnancy, lactation, expected survival <18 months, renal impairment, clinically important liver disease, or persistent elevation of the aminotransferase level >3 times the upper limit of normal.
- Intervention: twice daily ximelagatran, 24 mg (n = 612), or placebo (n = 611) for 18 months. All patients discontinued anticoagulant therapy but did not begin study treatment until the international normalised ratio (INR) was <1.5.
- Outcomes: VTE (recurrent DVT and PE), major and minor bleeding, and all cause mortality.
- Patient follow up: 1223 patients (99%) (mean age 57 y, 53% men) were included in the intention to treat analysis.

*See glossary.
†Information provided by author.

MAIN RESULTS

Fewer patients who received ximelagatran had recurrent VTE events than did patients who received placebo (table). Groups did not differ for major or minor bleeding or for all cause mortality (table).

CONCLUSION

In patients with deep venous thrombosis or pulmonary embolism receiving standard anticoagulant therapy for 6 months, ximelagatran reduced recurrent venous thromboembolism and did not increase bleeding.

Abstract and commentary also appear in ACP Journal Club.

For correspondence: Dr S Schulman, Karolinska Hospital, Stockholm, Sweden. sam.schulman@ki.se
Source of funding: AstraZeneca Research and Development.

Commentary—continued from previous page

T he optimal long term treatment of patients who present with unprovoked (or idiopathic) VTE is controversial. 15%–30% of patients with idiopathic VTE will have recurrent VTE in the first year after 3–6 months of anticoagulation. Prolonging the duration of anticoagulation beyond 3–6 months may delay recurrences while exposing patients to the haemorrhagic risk associated with extended anticoagulation. The possibility that a lower intensity warfarin regimen (INR 1.5–1.9) would allow safer anticoagulation without compromising efficacy was trumped by the results of another study that showed that conventional intensity anticoagulation (INR 2.0–3.0) has better efficacy than a lower intensity regimen. The results of the trial by Schulman et al show that long term ximelagatran therapy, administered orally in a fixed dose and without laboratory monitoring, is effective for preventing recurrent VTE in patients who received 6 months of conventional anticoagulant therapy and is not associated with an increased haemorrhagic risk.

However, the extent to which ximelagatran prevented recurrent VTE was not different from that of oral anticoagulants in the many trials that addressed their benefit. Furthermore, the apparent lack of haemorrhagic potential may have been because of the unusually high rate of bleeding in patients who received placebo. Finally, in about 6% of patients, aminotransferase concentrations increased to >3 times the upper limit of normal. Additional research is required to identify the optimal strategy of long term anticoagulation in patients with idiopathic VTE. There is the potential that disease recurrence can be predicted on an individual basis after 3–6 months of conventional therapy if venous ultrasonography shows persistent abnormalities or D dimer levels are elevated.

Paolo Prandoni, MD
University of Padua
Padua, Italy


**Ximelagatran v placebo for secondary prevention of venous thromboembolism (VTE) at 18 months**

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Ximelagatran</th>
<th>Placebo</th>
<th>RRR (95% CI)</th>
<th>NNT (CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>VTE</td>
<td>2.8%</td>
<td>12.6%</td>
<td>83% (69 to 90)</td>
<td>10 (9 to 12)</td>
</tr>
<tr>
<td>All cause mortality</td>
<td>1.1%</td>
<td>1.4%</td>
<td>17% (–143 to 72)</td>
<td>Not significant</td>
</tr>
<tr>
<td>Major bleeding</td>
<td>1.1%</td>
<td>1.3%</td>
<td>16% (–65 to 273)</td>
<td>Not significant</td>
</tr>
<tr>
<td>Major and minor bleeding</td>
<td>23.9%</td>
<td>21.0%</td>
<td>16% (–6 to 44)</td>
<td>Not significant</td>
</tr>
</tbody>
</table>

*Abbreviations defined in glossary: RRR, RR, NNT, NNH, and CI calculated using Cox proportional hazards ratio in article.
Ximelagatran prevented secondary venous thromboembolism

Evid Based Med 2004 9: 107
doi: 10.1136/ebm.9.4.107

Updated information and services can be found at:
http://ebm.bmj.com/content/9/4/107

These include:

References
This article cites 6 articles, 1 of which you can access for free at:
http://ebm.bmj.com/content/9/4/107#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
- Drugs: cardiovascular system (754)
- Stroke (546)
- Venous thromboembolism (109)
- Epidemiologic studies (1092)
- Pulmonary embolism (73)
- Unwanted effects / adverse reactions (35)
- Clinical trials (epidemiology) (1594)
- Liver disease (55)
- Pregnancy (333)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/